Jesse Doran
Cardiovascular Disease · Baltimore, MDNPI 1538587704
Payments from drug & device makers
Across 492 payments — averaging $2280.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$400K
- Novo Nordisk AS$337K
- Merck$180K
- AstraZeneca$96K
- Boehringer Ingelheim Pharma GmbH & Co.kg$43K
- Pfizer$33K
- plus $32K from 12 others
Across 1 payment — averaging $50.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$50
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 255 | $400,149 |
| Novo Nordisk AS | 139 | $337,460 |
| Merck | 13 | $179,598 |
| AstraZeneca | 6 | $95,858 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 10 | $43,229 |
| Pfizer | 11 | $33,499 |
| Bayer | 6 | $28,130 |
| Organon | 2 | $2,743 |
| Boehringer Ingelheim | 17 | $328 |
| Novartis | 14 | $241 |
| Novo Nordisk | 7 | $237 |
| E.r. Squibb & Sons, L.L.C. | 5 | $192 |
| Biosense Webster, Inc. | 1 | $119 |
| Abbott | 2 | $49 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
How this compares
$1,121,893 in reported general payments places this provider in the 95th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Baltimore
- Christopher DefilippiBaltimore$9.2M
- Thorsten LeuckerBaltimore$7.1M
- Joao LimaBaltimore$5.6M
- Jeffrey ColeBaltimore$4.8M
- Carlos InceBaltimore$3M
- Paul GurbelBaltimore$2.6M
- Navin KapurBaltimore$1.8M
- Robert WeissBaltimore$1.4M
- Stephen GottliebBaltimore$1.4M
- Armin Arbab-ZadehBaltimore$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.